SG11201804884PA - Method for modulating autophagy and applications thereof - Google Patents

Method for modulating autophagy and applications thereof

Info

Publication number
SG11201804884PA
SG11201804884PA SG11201804884PA SG11201804884PA SG11201804884PA SG 11201804884P A SG11201804884P A SG 11201804884PA SG 11201804884P A SG11201804884P A SG 11201804884PA SG 11201804884P A SG11201804884P A SG 11201804884PA SG 11201804884P A SG11201804884P A SG 11201804884PA
Authority
SG
Singapore
Prior art keywords
autophagy
jakkur
centre
bangalore
lab
Prior art date
Application number
SG11201804884PA
Inventor
Ravi Manjithaya
Piyush Mishra
Natesan Suresh Santhi
Somya Bats
Veena Ammanathan
Aravinda Chavalmane
Original Assignee
Jawaharlal Nehru Centre For Advanced Scient Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jawaharlal Nehru Centre For Advanced Scient Research filed Critical Jawaharlal Nehru Centre For Advanced Scient Research
Publication of SG11201804884PA publication Critical patent/SG11201804884PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11 M1111101110101011111 HO 11111 0101101HEIM1100 1111111110111011# International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... .....!;,' WO 2017/098467 Al 15 June 2017(15.06.2017) WIPO I PCT (51) International Patent Classification: Aravinda; Autophagy lab, Molecular Biology and Genet- A61K 31/277 (2006.01) A61K 31/443 (2006.01) ics Unit, Jawaharlal Nehru Centre for Advanced Scientific A61K 31/325 (2006.01) A61P 25/00 (2006.01) Research, Jakkur, Bangalore 560064 (IN). A61K 31/352 (2006.01) A61P 25/28 (2006.01) A61K 31/4025 (2006.01) A61P 25/16 (2006.01) (74) Agents: MUKHARYA, Durgesh et al.; K&S Partners, 4121/B, 6th Cross, 19A Main, HAL II Stage (Extension), (21) International Application Number: Bangalore Karnataka 560 038 (IN). PCT/IB2016/057498 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: 9 December 2016 (09.12.2016) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (30) Priority Data: 6596/CHE/2015 9 December 2015 (09.12.2015) IN MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (71) Applicant: JAWAHARLAL NEHRU CENTRE FOR RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. ADVANCED SCIENTIFIC RESEARCH [IN/IN]; Jakkur, Karnataka, Bangalore 560064 (IN). (84) Designated States (unless otherwise indicated, for every (72) Inventors: MANJITHAYA, Ravi; Autophagy lab, Mo- _ lecular Biology and Genetics Unit, Jawaharlal Nehru kind of regional protection available): ARIPO (BW, GH, Centre for Advanced Scientific Research, Jakkur, Ban- galore 560064 (IN). MISHRA, Piyush; Autophagy lab, Molecular Biology and Genetics Unit, Jawaharlal Nehru GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, — _ _ Centre for Advanced Scientific Research, Jakkur, Ban- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: = galore 560064 (IN). SANTHI NATESAN, Suresh; Auto- phagy lab, Molecular Biology and Genetics Unit, Jawa- harlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064 (IN). BATS, Somya; Auto- = = lab, Molecular Biology and Genetics Unit, Jawa- phagy harlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064 (IN). AMMANATHAN, of inventorship (Rule 4.17(iv)) Published: Veena; Autophagy lab, Molecular Biology and Genetics = Unit, Jawaharlal Nehru Centre for Advanced Scientific Re- with international search report (Art. 21(3)) = search, Jakkur, Bangalore 560064 (IN). CHAVALMANE, = = = = = = 1-1 IN 7r GC t:t © IN 1-1 (54) Title: METHOD FOR MODULATING AUTOPHAGY AND APPLICATIONS THEREOF 0 ei (57) : The present disclosure relates to method of modulating autophagy by modulators of autophagy, wherein the auto - en. ) phagy includes but is not limited to macroautophagy, chaperone mediated autophagy and microautophagy. The present disclosure further relates to modulators of autophagy for increasing or decreasing the autophagic flux. The disclosure also relates to modulator per se in modulating autophagy including but not limiting to macroautophagy, chaperon mediated autophagy and microautophagy.
SG11201804884PA 2015-12-09 2016-12-09 Method for modulating autophagy and applications thereof SG11201804884PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN6596CH2015 2015-12-09
PCT/IB2016/057498 WO2017098467A1 (en) 2015-12-09 2016-12-09 Method for modulating autophagy and applications thereof

Publications (1)

Publication Number Publication Date
SG11201804884PA true SG11201804884PA (en) 2018-07-30

Family

ID=57681685

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804884PA SG11201804884PA (en) 2015-12-09 2016-12-09 Method for modulating autophagy and applications thereof

Country Status (5)

Country Link
US (1) US20180369186A1 (en)
EP (1) EP3386498A1 (en)
AU (2) AU2016366810A1 (en)
SG (1) SG11201804884PA (en)
WO (1) WO2017098467A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109384782A (en) * 2017-08-04 2019-02-26 厦门大学 Substituted five-membered and hexa-member heterocycle class compound, preparation method, pharmaceutical composition and application thereof
JOP20180094A1 (en) * 2017-10-18 2019-04-18 Hk Inno N Corp Heterocyclic compound as a protein kinase inhibito
US11801284B2 (en) 2017-12-13 2023-10-31 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating motor neuron diseases
WO2019194939A1 (en) * 2018-04-02 2019-10-10 The Children's Medical Center Corporation Methods and compositions relating to the inhibition of ip6k1
CN110812348A (en) * 2018-08-13 2020-02-21 天津科技大学 Novel application of quaternary ammonium compound
US20240226063A1 (en) * 2021-04-29 2024-07-11 Jawaharlal Nehru Centre For Advanced Scientific Research Soluble analogues of 6bio thereof and implementation thereof
EP4183449A1 (en) * 2021-11-17 2023-05-24 Samsara Therapeutics Inc. Autophagy inducing compounds and uses thereof
WO2024199341A1 (en) * 2023-03-30 2024-10-03 浙江海正药业股份有限公司 Fused polycyclic derivative and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011146879A2 (en) * 2010-05-20 2011-11-24 University Of Rochester Methods and compositions related to modulating autophagy

Also Published As

Publication number Publication date
AU2016366810A1 (en) 2018-06-28
AU2019275604A1 (en) 2020-01-02
WO2017098467A1 (en) 2017-06-15
US20180369186A1 (en) 2018-12-27
EP3386498A1 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
SG11201804884PA (en) Method for modulating autophagy and applications thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201908391XA (en) Methods for modulating an immune response
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201808990QA (en) Compositions for topical application of compounds
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201804694SA (en) Dual controls for therapeutic cell activation or elimination
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201906947SA (en) Antibodies to alpha-synuclein and uses thereof
SG11201808598UA (en) Detecting microbial infection in wounds
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201806853VA (en) Abstracted graphs from social relationship graph
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201805001UA (en) Method of treating influenza a
SG11201804916PA (en) Three-dimensional polymer networks with channels situated therein
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201805898RA (en) Liquid composition comprising a multistage polymer, its method of preparation and its use
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201804867RA (en) Coating compositions and treating method
SG11201805649UA (en) Therapeutic anti-cd9 antibody
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201804587QA (en) Isoindole compounds